Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
General22 hours agoEmergency operation underway after reports of bodies north-east of Falls Creek
-
Noosa News23 hours agoExclusion zone declared as bushfire sparks major emergency response near Brisbane
-
Noosa News22 hours agoMan arrested after gaining ‘unauthorised’ access to Amberley RAAF base
-
Noosa News24 hours agoPSPA declared, Camp Mountain – Sunshine Coast